As the global orphan drug market has been evolving and growing at an accelerating pace over the last few years, providing new attractive commercial opportunities, biotech and pharmaceutical companies developing drug products for low-prevalence or rare diseases face a set of complex challenges. Turning their successful R&D into a profitable business model to commercialize their products and make them available to treat patients with unmet medical needs is one of the key challenges.
Medunik Canada is joining us this year as a sponsor of the World Orphan Drug Congress, taking place this year in November, in Geneva Switzerland.
Highlights from the agenda include:
Ultra-orphan therapies – broad skills for small populations
Martin Mackay, EVP & Global Head of R&D, Alexion Pharmaceuticals
How to optimise clinical development and demonstrate value for an orphan drug
Rogerio Vivaldi, SVP and Head of Rare Diseases, Genzyme
Understanding the complexity of rare disease research
Arthur Tzianabos, SVP, Head of Research, Shire HGT
Discover new policy principles scenarios on rare disease patient registries
Yann Le Cam, Chief Executive Officer, Eurordis
For more information and to register to attend, please visit the website >